1st quarter 2020 revenue
- Revenue growth over 1st quarter 2020
- +1.0% at current exchange rates at €199.2m
- +1.4% at constant exchange rates at €199.9 million
- Activity affected by the COVID-19 crisis in the 2nd quarter
Villepinte,
In millions of euros, at | Change (%) | Q1 2020 at current exchange rates | Change (%) | Q1 2020 at constant exchange rates | Reported Q1 2019 |
Sales in | -14.3% | 79.7 | -14.4% | 79.6 | 93.0 |
Sales in Other Markets | +14.6% | 119.5 | +15.3% | 120.3 | 104.3 |
Total | +1.0% | 199.2 | +1.4% | 199.9 | 197.3 |
Sales driven by
In
Revenue in the
In
Analysis of sales by activity
Diagnostic Imaging sales increased 0.2% (+0.8% at constant exchange rates) and reached €172.2 million compared with €171.9 million in the same period in 2019.
- MRI2 sales amounted to €64.4 million, down 3% (-3.2% at constant exchange rates) compared with €66.4 million in the same period in 2019. The main reason is a price effect with the arrival of the generic of Dotarem® in most countries of the
- CT/Cath Lab2 revenue grew 2.3% to €107 million (+3.5% at constant exchange rates) thanks to the good level of sales of Xenetix® with stable sales of Optiray®.
Still driven by Lipiodol®, Interventional Imaging had double-digit sales growth (+14.8%) with €19.2 million in revenue (+13.3% at constant exchange rates).
2020 outlook: an April expected to be down considerably due to the COVID-19 crisis, with a gradual recovery expected in May-June
Lockdown measures in various countries in response to the COVID-19 crisis are having significant impacts on April sales, which are expected to drop drastically (between -30% and -35%). The strong mobilization of the hospital sector in fighting the epidemic has resulted in a sudden, temporary slowdown in consultations and everyday medical examinations.
However, despite this unprecedented situation in health and business,
As a precaution under these circumstances,
Against a background of economic uncertainty, the Group has a solid balance sheet and sufficient bank credit lines to cover its liquidity requirements even in an environment with little visibility.
[1] At constant exchange rates: amounts and rates of growth are calculated by canceling out the exchange rate effect, which is defined as the difference between the indicator’s value for period N, converted at the exchange rate for period N-1, and the indicator’s value for period N-1.
2 As a reminder, the
Upcoming events:
Publication of 2020 half-year revenue
About
Forward-looking statements
Certain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group’s actual performance and results and those presented explicitly or implicitly by these forward-looking statements.
These forward-looking statements are valid only as of the date of this press release, and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group’s control. These risks and uncertainties include but are not limited to the uncertainties inherent in research and development, future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatory authorities (such as the
For more information about
Contacts
Actifin |
Jérôme Estampes Chief Financial Officer +33 (0)1 45 91 50 00 | +33 (0)1 56 88 11 25 blehari@actifin.fr Press Jennifer Jullia +33 (0)1 56 88 11 19 jjullia@actifin.fr |
Attachment
- 04232020-Revenue at 1st quarter 2020
Source:
2020 GlobeNewswire, Inc., source